UnitedHealthcare · Veozah Vms · US health-plan appeal rights

Veozah Vms denied as not FDA-approved for this use by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Veozah Vms denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: OptumRx Prior Authorization — Veozah (Fezolinetant) for VMS

The UnitedHealthcare angle on Veozah Vms

## Why UHC May Issue a Not-FDA-Approved Denial for Veozah

Veozah (fezolinetant) received FDA approval in May 2023 for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. A "not-FDA-approved" denial from UnitedHealthcare most commonly results from one of two scenarios: (1) UHC's internal coverage policy or claims system has not yet been updated to reflect the 2023 approval, causing an automated denial; or (2) the diagnosis or indication on the submitted claim does not precisely match the FDA-approved indication language, creating a technical mismatch even though the use is clinically on-label.

## Why This Is Appealable

This denial type is factually incorrect as applied to an on-label use of Veozah. Under the ACA, ERISA, and established case law, an insurer cannot deny coverage of an FDA-approved drug used within its approved indication on the grounds that the drug lacks approval. The denial contradicts the drug's regulatory status and is highly likely to be overturned — particularly at external review, where independent reviewers are not bound by UHC's internal policy and apply objective regulatory standards.

## Federal Appeal Framework

Internal appeal (ACA/ERISA §503): File immediately. Attach the FDA approval letter and the official prescribing label. Because the denial is factually incorrect, internal appeals in this category are frequently resolved at the first level. Standard timeline: 30 days; expedited: 72 hours.
Expedited appeal: Request if the delay is causing clinical harm or significantly impairing function.
External review (ACA §2719): If the internal appeal fails — which would be unusual for a clear FDA-approval mismatch — escalate to independent external review within approximately four months of the final internal denial. This denial type has a high external-review reversal rate.

## Documentation to Gather

1. FDA approval and prescribing label: Print or cite the current FDA-approved prescribing label for Veozah, specifically the Indications and Usage section confirming approval for moderate-to-severe VMS due to menopause. 2. Diagnosis confirmation: Clinical documentation confirming the diagnosis of menopause and moderate-to-severe VMS, using ICD-10 codes that map precisely to the approved indication. 3. Claim/authorization documentation: Confirm that the submitted NDC code, HCPCS code, and diagnosis code are correct and match what was submitted, to rule out a coding mismatch as the source of the denial. 4. UHC's coverage policy: Request UHC's current coverage determination for fezolinetant/Veozah. If the policy predates May 2023 or has not been updated, that is direct evidence of an administrative error. 5. Prescriber letter: Brief letter from the treating clinician confirming on-label use and attaching the FDA prescribing label.

## Criteria-Mapping Structure for Your Appeal Letter

| Denial Basis | Your Rebuttal | |---|---| | Drug is not FDA-approved | Cite FDA approval date (May 2023) and attach or reference the prescribing label | | Use is outside approved indication | Confirm ICD-10 code and clinical diagnosis match the approved indication exactly | | UHC policy does not cover this drug | Argue policy must be consistent with FDA-approved status; request updated policy | | Coding or submission error | Verify and correct any NDC/HCPCS/ICD-10 mismatch |

A concise, document-heavy appeal — FDA label attached, codes verified, prescriber letter included — is the fastest path to reversal for this denial type.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Veozah Vms

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.